The suspect is narrowed down to Thomas Mathers (Dallas Roberts) and he takes a DNA test, but Stabler doesn't believe he did it because he is a closeted ...
William Cohn - Chestnut Hill MA, US Thomas P. Mathers - Newbury MA, US
Assignee:
Beth Israel Deaconess Medical Center - Boston MA Teleflex Incorporated - Limerick PA
International Classification:
A61B 17/04
US Classification:
606148, 606228
Abstract:
A suture system includes a plurality of double-stranded needles connected in sequence with a single-stranded needle at each end. The double-stranded suture needles incorporates two suture strands into a single needle. The suture system of the present invention facilitates the implantation of valve prostheses.
Synthesis Of Directed Sequence Polymer Compositions And Antibodies Thereof For The Treatment Of Protein Conformational Disorders
The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder.
Methods For Designing And Preparing Vaccines Comprising Directed Sequence Polymer Compositions Via The Directed Expansion Of Epitopes
The instant invention comprises a process of preparing a composition comprising directed sequence polymer (DSP) mixtures that act as epitopes and useful as vaccines, such DSP synthesized according to a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use as a vaccine, preferably for infectious agents that are immune evasive.
William Cohn - Chestnut Hill MA, US Thomas P. Mathers - Newburyport MA, US
International Classification:
A61B 17/04
US Classification:
606147
Abstract:
A suture system includes a plurality of double-stranded needles connected in sequence with a single-stranded needle at each end. The double-stranded suture needles incorporates two suture strands into a single needle. The suture system of the present invention facilitates the implantation of valve prostheses.
William Cohn - Chestnut Hill MA Thomas P. Mathers - Newbury MA
Assignee:
Beth Israel Deaconess Medical Center - Boston MA Genzyme Corporation - Cambridge MA
International Classification:
A61B 1704
US Classification:
606148, 606228, 623 211
Abstract:
A suture system includes a plurality of double-stranded needles connected in sequence with a single-stranded needle at each end. The double-stranded suture needles incorporates two suture strands into a single needle. The suture system of the present invention facilitates the implantation of valve prostheses.
Directed Sequence Polymer Compositions And Antibodies Thereof For The Treatment Of Protein Conformational Disorders
- Boxford MA, US Eric Zanelli - Sudbury MA, US Thomas P. Mathers - Boxford MA, US
Assignee:
DECLION PHARMACEUTICALS, INC. - Boxford MA
International Classification:
C07K 1/04 C07K 16/18
US Classification:
4241301, 435 704, 506 30
Abstract:
The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder.
Name / Title
Company / Classification
Phones & Addresses
Thomas Paul Mathers President, CEO, Ceo, And Director, President Chief Executive Officer
PEPTIMMUNE, INC Commercial Physical Research · Scientists-Consulting · Other Technical Consulting Svcs
64 Sydney St, Cambridge, MA 02139 64 Sidney St, Cambridge, MA 02139 PO Box 440526, Somerville, MA 02144 (617)7158000, (617)6618855
Resumes
Chief Executive Officer At Colucid Pharmaceuticals, Inc
CureFAKtor Pharmaceuticals, LLC - Roswell Park Cancer Institute, Buffalo, NY since 2012
Director
CoLucid Pharmaceuticals, Inc since Jun 2011
Chief Executive Officer
Déclion Holdings LLC since Mar 2011
Chairman and CEO
Peptimmune, Inc. 2003 - Jun 2011
President & CEO
Cell Based Delivery 2002 - 2003
President & CEO
Education:
United States Military Academy at West Point 1984 - 1988
Bachelor of Science
We are excited that lasmiditan will be back at Lilly, where it was originally discovered, for the conclusion of phase 3 development and potential commercialization, said Thomas Mathers, CoLucid's CEO.